Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Holdings Corp," but the filing text identifies the registrant as Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2017
Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock and warrants.

Key Financial Metrics

  • Gross Proceeds: Approximately $11.7 million.
  • Net Proceeds: Approximately $10.9 million (after deducting placement agent fees and estimated offering expenses).
  • Securities Issued: 3,732,356 shares of Common Stock and warrants to purchase 1,866,178 shares.
  • Purchase Price: $3.14 per share and related warrant.
  • Warrant Exercise Price: $4.10 per share.
  • Placement Agent Fee: 6.5% of gross proceeds.
  • Expense Reimbursement: Up to $35,000 for out-of-pocket expenses.

Material Changes and Transaction Details

The Company entered into a Securities Purchase Agreement on April 2, 2017, to raise capital through a registered direct offering. The transaction involves the issuance of new equity and warrants, representing a material change in the Company's capital structure. The offering is expected to close on or about April 6, 2017, subject to customary closing conditions.

Guidance, Outlook, and Use of Proceeds

Management intends to use the net proceeds for operations and general corporate purposes, specifically targeting:

  • Clinical, sales, and marketing initiatives to accelerate adoption in the rehabilitation market.
  • Research, development, and commercialization of a robotic exoskeleton for home use.
  • Development and commercialization of able-bodied exoskeletons for industrial use.

Restrictions: Purchasers are subject to "leak-out" agreements restricting sales until May 20, 2017, limiting sales to 30% of daily trading volume unless the stock price exceeds $4.25.

Investor Verification Checklist

  • Verify the closing date of the offering (expected April 6, 2017) and confirmation of net proceeds received.
  • Review the full text of the Warrant (Exhibit 4.1) and Securities Purchase Agreement (Exhibit 10.1) for specific terms and conditions.
  • Monitor the Company's stock price relative to the $4.25 threshold which affects leak-out restrictions for purchasers.
  • Confirm the allocation of funds to the specific R&D and commercialization projects outlined in the use of proceeds.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.